May 23rd, 2007
For Drug Makers, a Downside to Full Disclosure
By Barry Meier
The New York Times
When GlaxoSmithKline settled a lawsuit three years ago with the State of New York over the antidepressant medication Paxil, the company agreed to take an unusual step: publicly disclosing the results of its clinical trials for Paxil and other drugs.
This week, GlaxoSmithKline learned what that greater disclosure could mean.